VEGFR2 (Luc) HEK293 Reporter Cell
描述（Description）
The Human VEGF R2 (Luc) HEK293 Reporter Cell was engineered to not only express NFAT signaling response element, but also express the receptor full length human VEGF R2 (Gene ID: 3791). When stimulated with human VEGF protein, the VEGF/VEGF R2 interaction drives NFAT-mediated luminescence. Inhibition of VEGF binding to VEGF R2 by either anti-VEGF or anti-VEGF R2 antibodies results in a decrease in luminescence.
應(yīng)用說(shuō)明（Application）
1. Screen for anti-human VEGF R2 or anti-human VEGF neutralizing antibody.
2. Screen for human VEGF R2 small molecule inhibitor
生長(zhǎng)特性（Growth Properties）
Adherent
篩選標(biāo)記（Selection Marker）
Hygromycin (50 μg/mL) + Puromycin (5 μg/mL)
培養(yǎng)基（Culture Medium）
DMEM medium + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲(chǔ)（Storage）
Frozen in liquid nitrogen.
支原體檢測(cè)（Mycoplasma Testing）
Negative
無(wú)菌檢測(cè)（Sterility Testing）
Negative
使用說(shuō)明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Vascular endothelial growth factor (VEGF) is a potent angiogenic inducer that stimulates the expression of tissue factor (TF), the major cellular initiator of blood coagulation. VEGF could inhibit apoptosis and increase cellular proliferation. As the most abundant splice variant of VEGF-A, VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2, leads to activation of the PI3K/AKT, p38 MAPK, FAK, and paxillin. Due to the angiogenesis ability of VEGF in cancer, interfering VEGF/VEGFR2 interaction has become an attractive method in cancer therapy.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： VEGFR2報(bào)告細(xì)胞系;VEGFR2報(bào)告細(xì)胞株;VEGFR2細(xì)胞系;VEGFR2細(xì)胞株;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。